摘要
目的通过对依折麦布联合阿托伐他汀钙降脂治疗的临床疗效观察，评价依折麦布在老年冠心病患者介入治疗术后血脂管理中的作用。方法选取在我院行冠状动脉介入治疗、血脂未达标的老年冠心病患者150例，数字抽签随机分为两组，对照组服用阿托伐他汀钙片治疗，实验组服用依折麦布片联合阿托伐他汀钙片治疗，比较两组治疗1个月后血脂的变化和不良反应发生情况。结果实验组血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）达标率分别为68例（90．7％）、62例（82．7％）和56例（74．7％），高于对照组50例（66．7％）、44例（58．7％）、38例（50．7％），两组比较差异有统计学意义（X^2值分别为12．87、10．42、9．23，均P〈0．01）。实验组和对照组不良反应发生率分别为5．3％（4例）、2．7％（2例），2组比较差异无统计学意义（X^2-0．17，P〉0．05）。结论依折麦布联合阿托伐他汀钙片治疗高脂血症的临床疗效优于单独使用阿托伐他汀钙片治疗，不增加不良反应。
Objective To observe the clinical efficacy of ezetimibe combined with atorvastatin calcium on hyperlipidemia, and to evaluate the role of ezetimibe on lipid management in elderly patients with coronary heart disease （CHD） after coronary intervention. Methods A total of 150 elderly CHD patients with hyperlipidemia to undergo coronary intervention in our hospital were selected. Patients were randomly divided into the control group and the experimental group （n： 75, each）. Patients in control group were treated with atorvastatin, and in the experimental group with ezetimibe plus atorvastatin. The change of blood lipids levels and the incidence of adverse reactions were compared between the two groups 1 month after the treatment. Results The numbers of patients with normal serum levels of total cholesterol （TC）, triglyeerides （TG）, low density lipoprotein （LDL C） were much more in the experimental group than in the control group after treatment [68 cases （90.7%） vs. 50 cases （66.7%）, 62 cases （82.7%） vs. 44 cases （58.7%）, 56 cases （74.7%） vs. 38 cases （50.7%）, X2 = 12.87, 10.42, 9.23, respectively, all P〈0.01]. There was no significant difference in the incidence of adverse reactions between the two groups [5.3% （4 case） vs. 2.7%（2 cases）, X2= 0.17, P〉 0.05%. Conclusions Compared with atorvastatin calcium treatment, ezetimibe combined with atorvastatin calcium treatment has a better clinical efficacy on hyperlipidemia with no increase of adverse reactions in elderly CHD patients.
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2013年第6期592-594,共3页
Chinese Journal of Geriatrics
关键词
降血脂药
冠心病
血管成形术
经腔
经皮冠状动脉
Antilipemic agents
Coronary disease
Angtoplasty, transluminal, percutanouscoronary
